9 min. read

E&O newsletter plans. DTx pricing.

Issue 076

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about the FDA's posteriorities -- these are one step below priorities -- for 2021, which include risk categories for SaMD and new guidance for devices related to opioid use disorder. I also put together some data on the rapid ascent of telehealth-related comments (76x y-o-y) on the

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Recent Articles